Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0AK5G
|
||||
| Former ID |
DIB003241
|
||||
| Drug Name |
RPAF-AH
|
||||
| Indication | Sepsis [ICD9: 995.91; ICD10:A40, A41] | Discontinued in Phase 3 | [1] | ||
| Company |
ICOS Corp
|
||||
| CAS Number |
CAS 76901-00-3
|
||||
| Target and Pathway | |||||
| Target(s) | Lipoprotein-associated phospholipase A2 | Target Info | Modulator | [2] | |
| KEGG Pathway | Ether lipid metabolism | ||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Pathway Interaction Database | Lissencephaly gene (LIS1) in neuronal migration and development | ||||
| WikiPathways | IL1 and megakaryotyces in obesity | ||||
| Synthesis, Secretion, and Deacylation of Ghrelin | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00037687) Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis. U.S. National Institutes of Health. | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006777) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.